메뉴 건너뛰기




Volumn 10, Issue 4, 2008, Pages 319-325

Insulin resistance and blood pressure

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; NIFEDIPINE; RENIN INHIBITOR; ROSIGLITAZONE; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; CARDIOVASCULAR AGENT; MINERALOCORTICOID RECEPTOR; RENIN;

EID: 52449104443     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0059-1     Document Type: Review
Times cited : (24)

References (43)
  • 1
    • 27444443876 scopus 로고    scopus 로고
    • American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement
    • Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
    • (2005) Circulation , vol.112 , pp. 2735-2752
    • Grundy, S.M.1    Cleeman, J.I.2    Daniels, S.R.3
  • 2
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 3
    • 0347423198 scopus 로고    scopus 로고
    • Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
    • Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
  • 4
    • 34548463434 scopus 로고    scopus 로고
    • Diabetes and hypertension: Epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions
    • Schutta MH: Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007, 2:124-130.
    • (2007) J Cardiometab Syndr , vol.2 , pp. 124-130
    • Schutta, M.H.1
  • 5
    • 33645225170 scopus 로고    scopus 로고
    • Glucose metabolism in patients with essential hypertension
    • Garcia-Puig J, Ruilope LM, Luque M, et al.: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318-326.
    • (2006) Am J Med , vol.119 , pp. 318-326
    • Garcia-Puig, J.1    Ruilope, L.M.2    Luque, M.3
  • 7
    • 34548391273 scopus 로고    scopus 로고
    • Skeletal muscle insulin resistance is fundamental to the cardiometabotic syndrome
    • Nistala, R, Stump CS: Skeletal muscle insulin resistance is fundamental to the cardiometabotic syndrome. J Cardiometab Syndr 2006, 1:47-52.
    • (2006) J Cardiometab Syndr , vol.1 , pp. 47-52
    • Nistala, R.1    Stump, C.S.2
  • 9
    • 38549134399 scopus 로고    scopus 로고
    • Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes
    • Takata Y, Osawa H, Krata M, et al.: Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51:534-539.
    • (2008) Hypertension , vol.51 , pp. 534-539
    • Takata, Y.1    Osawa, H.2    Krata, M.3
  • 10
    • 33748305533 scopus 로고    scopus 로고
    • The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
    • Diamant M, Tushuizen M: The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD? Curr Diab Rep 2006, 6:279-286.
    • (2006) Curr Diab Rep , vol.6 , pp. 279-286
    • Diamant, M.1    Tushuizen, M.2
  • 11
    • 21744452983 scopus 로고    scopus 로고
    • PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
    • Clasen R, Schupp M, Foryst-Ludwig A, et al.: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
    • (2005) Hypertension , vol.46 , pp. 137-143
    • Clasen, R.1    Schupp, M.2    Foryst-Ludwig, A.3
  • 12
    • 34249003028 scopus 로고    scopus 로고
    • The role of c-reactive protein in the metabolic syndrome and diabetes mellitus
    • Sowers JR: The role of c-reactive protein in the metabolic syndrome and diabetes mellitus. Endocrinologist 2007, 17:163-168.
    • (2007) Endocrinologist , vol.17 , pp. 163-168
    • Sowers, J.R.1
  • 13
    • 35148840913 scopus 로고    scopus 로고
    • Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
    • Cooper SA, Whaley-Connell A, Habibi J, et al.: Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2209-H2223.
    • (2007) Am J Physiol Heart Circ Physiol , vol.293
    • Cooper, S.A.1    Whaley-Connell, A.2    Habibi, J.3
  • 15
    • 20044376702 scopus 로고    scopus 로고
    • The pathobiology of diabetic complications: A unifying mechanism
    • Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
    • (2005) Diabetes , vol.54 , pp. 1615-1625
    • Brownlee, M.1
  • 16
    • 34547443383 scopus 로고    scopus 로고
    • Adiponectin and insulin sensitivity in primary aldosteronism
    • Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855-861.
    • (2007) Am J Hypertens , vol.20 , pp. 855-861
    • Fallo, F.1    Della Mea, P.2    Sonino, N.3
  • 17
    • 36148934920 scopus 로고    scopus 로고
    • The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study
    • Brouwer BG, Visseren FLJ, van der Graff Y: The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. Am Heart J 2007, 154:1146-1152.
    • (2007) Am Heart J , vol.154 , pp. 1146-1152
    • Brouwer, B.G.1    Visseren, F.L.J.2    van der Graff, Y.3
  • 18
    • 26444457387 scopus 로고    scopus 로고
    • Effect of exercise training on plasma levels of c-reactive protein in healthy adults: The heritage family study
    • Lakka TA, Lakka HM, Rankinen T, et al.: Effect of exercise training on plasma levels of c-reactive protein in healthy adults: the heritage family study. Eur Heart J 2005, 26:2018-2025.
    • (2005) Eur Heart J , vol.26 , pp. 2018-2025
    • Lakka, T.A.1    Lakka, H.M.2    Rankinen, T.3
  • 19
    • 0842333082 scopus 로고    scopus 로고
    • Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort
    • McKeown N, Meigs JB, Liu S, et al.: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27:538-546.
    • (2004) Diabetes Care , vol.27 , pp. 538-546
    • McKeown, N.1    Meigs, J.B.2    Liu, S.3
  • 20
    • 39549111696 scopus 로고    scopus 로고
    • Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC)
    • Lutsey PL, Steffen LM, Stevens J.: Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC). Circulation 2008, 117:754-761.
    • (2008) Circulation , vol.117 , pp. 754-761
    • Lutsey, P.L.1    Steffen, L.M.2    Stevens, J.3
  • 21
    • 2342652390 scopus 로고    scopus 로고
    • Adverse prognostic significance of new diabetes in treated hypertensive subjects
    • Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:1-7.
    • (2004) Hypertension , vol.43 , pp. 1-7
    • Verdecchia, P.1    Reboldi, G.2    Angeli, F.3
  • 22
    • 33746367481 scopus 로고    scopus 로고
    • Antihypertensive medications and the risk of incident type 2 diabetes
    • Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065-1070.
    • (2006) Diabetes Care , vol.29 , pp. 1065-1070
    • Taylor, E.N.1    Hu, F.B.2    Curhan, G.C.3
  • 23
    • 34548428300 scopus 로고    scopus 로고
    • Treatment of hypertension with thiazides: Benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance
    • Shargorodsky M, Boaz M, Davidovitz I, et al.: Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. J Cardiometab Syndr 2007, 2:16-23.
    • (2007) J Cardiometab Syndr , vol.2 , pp. 16-23
    • Shargorodsky, M.1    Boaz, M.2    Davidovitz, I.3
  • 24
    • 33749061108 scopus 로고    scopus 로고
    • Metabolic safety of antihypertensive drugs: Myth vs. reality
    • Stas S, Appesh L, Sowers JR: Metabolic safety of antihypertensive drugs: myth vs. reality. Curr Hypertens Rep 2006, 8:403-408.
    • (2006) Curr Hypertens Rep , vol.8 , pp. 403-408
    • Stas, S.1    Appesh, L.2    Sowers, J.R.3
  • 25
    • 33644842033 scopus 로고    scopus 로고
    • Development of diabetes with thiazide diuretics: The potassium issue
    • Carter BL, Basile J: Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens 2005, 7:638-640.
    • (2005) J Clin Hypertens , vol.7 , pp. 638-640
    • Carter, B.L.1    Basile, J.2
  • 26
    • 56349172623 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial
    • Stevo J, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial. Lancet 2004, 28:221-226.
    • (2004) Lancet , vol.28 , pp. 221-226
    • Stevo, J.1    Kjeldsen, S.E.2    Weber, M.3
  • 27
    • 38749150577 scopus 로고    scopus 로고
    • Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Wright JT, Harris-Haywood S, Pressel S, et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008, 168:207-217.
    • (2008) Arch Intern Med , vol.168 , pp. 207-217
    • Wright, J.T.1    Harris-Haywood, S.2    Pressel, S.3
  • 28
    • 9144236380 scopus 로고    scopus 로고
    • Recommendations for special populations: The treatment of hypertension in diabetes mellitus
    • Tan AS, Kuppuswamy S, Whaley-Connell AT, et al.: Recommendations for special populations: the treatment of hypertension in diabetes mellitus. Endocrinologist 2004, 14:368-381.
    • (2004) Endocrinologist , vol.14 , pp. 368-381
    • Tan, A.S.1    Kuppuswamy, S.2    Whaley-Connell, A.T.3
  • 29
    • 34250638587 scopus 로고    scopus 로고
    • Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus
    • Bank AJ, Kelly AS, Thelen AM, et al.: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hyperten 2007, 20:777-783.
    • (2007) Am J Hyperten , vol.20 , pp. 777-783
    • Bank, A.J.1    Kelly, A.S.2    Thelen, A.M.3
  • 30
    • 7744237066 scopus 로고    scopus 로고
    • Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
    • Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
    • (2004) JAMA , vol.292 , pp. 2227-2236
    • Bakris, G.L.1    Fonseca, V.2    Katholi, R.E.3
  • 31
    • 32944461232 scopus 로고    scopus 로고
    • Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients
    • Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertension 2006, 24:591-596.
    • (2006) J Hypertension , vol.24 , pp. 591-596
    • Celik, T.1    Iyisoy, A.2    Kursaklioglu, H.3
  • 32
    • 33845366982 scopus 로고    scopus 로고
    • Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
    • Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
    • (2007) J Hypertens , vol.25 , pp. 217-226
    • Villamil, A.1    Chrysant, S.G.2    Calhoun, D.3
  • 33
    • 40049111351 scopus 로고    scopus 로고
    • Antihypertensive therapy with aliskiren
    • Luft FC, Weinberger MH: Antihypertensive therapy with aliskiren. Kidney Int 2008, 73:679-683.
    • (2008) Kidney Int , vol.73 , pp. 679-683
    • Luft, F.C.1    Weinberger, M.H.2
  • 34
    • 24144490705 scopus 로고    scopus 로고
    • The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes
    • Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261-2266.
    • (2005) Diabetes Care , vol.28 , pp. 2261-2266
    • Gillespie, E.L.1    White, C.M.2    Kardas, M.3
  • 35
    • 33749590988 scopus 로고    scopus 로고
    • DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes
    • Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
    • (2006) N Engl J Med , vol.355 , pp. 1551-1562
    • Bosch, J.1    Yusuf, S.2    Gerstein, H.C.3
  • 36
    • 34548420712 scopus 로고    scopus 로고
    • Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
    • Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
  • 37
    • 0037160969 scopus 로고    scopus 로고
    • LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol
    • Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004-1010.
    • (2002) Lancet , vol.359 , pp. 1004-1010
    • Lindholm, L.H.1    Ibsen, H.2    Dahlof, B.3
  • 38
    • 0042154108 scopus 로고    scopus 로고
    • Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)
    • Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003, 21:1563-1574.
    • (2003) J Hypertension , vol.21 , pp. 1563-1574
    • Lindholm, L.H.1    Persson, M.2    Alaupovic, P.3
  • 39
    • 34548731369 scopus 로고    scopus 로고
    • Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome
    • Ichikawa Y: Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331-136.
    • (2007) Intern Med , vol.46 , pp. 1331-2136
    • Ichikawa, Y.1
  • 40
    • 0033517302 scopus 로고    scopus 로고
    • The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
    • Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
    • (1999) N Engl J Med , vol.341 , pp. 709-717
    • Pitt, B.1    Zannad, F.2    Remme, W.J.3
  • 41
    • 0037417252 scopus 로고    scopus 로고
    • Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    • Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
    • (2003) N Engl J Med , vol.348 , pp. 1309-1321
    • Pitt, B.1    Remme, W.2    Zannad, F.3
  • 42
    • 34547136451 scopus 로고    scopus 로고
    • Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling
    • Stas S, Whaley-Connell A, Habibi J, et al.: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148:3773-3780.
    • (2007) Endocrinology , vol.148 , pp. 3773-3780
    • Stas, S.1    Whaley-Connell, A.2    Habibi, J.3
  • 43
    • 20544453256 scopus 로고    scopus 로고
    • Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
    • Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
    • (2005) Circulation , vol.111 , pp. 3087-3094
    • Fiebeler, A.1    Nussberger, J.2    Shagdarsuren, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.